Fibrolamellar Cancer Foundation Helps Lead Liver Cancer Awareness Month
Industry: Cancer Awareness
Fatal Liver Cancer Striking Teens/Young Adults Pushes for Research, Treatments
Greenwich, CT (PRUnderground) October 11th, 2017
While October is well known as the “pink” breast cancer awareness month, the Fibrolamellar Cancer Foundation (FCF) reminds the world to think “green” as October is also Liver Cancer Awareness Month.
Fibrolamellar is a very rare form of liver cancer that generally attacks teens and young adults with healthy livers. Sadly, it has a very low survival rate and limited treatment options.
“Unfortunately, there are more types of cancer than there are months of the year,” John Hopper, President of the Greenwich-CT based FCF and Co-Chair of the GI Cancers Alliance (GICA) asserted. “Since Fibrolamellar is such a rare and aggressive cancer, Liver Cancer Awareness Month creates an important opportunity to spread the word about the great need for research funding.”
This October, FCF looks to heighten awareness of its green logo, in communicating that Fibrolamellar, and all types of cancers, continually need research funding. “Research for treatments or cures for all cancers are a united goal,” Hopper said. “We’re all invested in doing everything we can in the battle against cancer.”
FCF is a leading funder of rare liver cancer research. Right now, FCF is working with medical and scientific teams at over a dozen prestigious research institutions, as well as the National Cancer Institute (NCI), to seek new treatments. FCF will host its second research gathering, Fibrolamellar Research Summit – Building a Roadmap Towards a Cure, which will be held in Stamford, Connecticut in early November. This summit will provide an important forum for collaborative exchange amongst some of the world’s top rare GI cancer MD’s and PhD’s from academia, industry and government.
About Fibrolamellar Cancer Foundation
FCF, a public 501c3 nonprofit organization based in Greenwich, CT, was founded in 2009 by 27-year-old Tucker Davis, who lost his life to Fibrolamellar in 2010. FCF has funded nearly $7 million in research at major institutions in the U.S. and internationally. With 100% of all donations going to research, all operating costs for the foundation are funded by the Charles A. and Marna Davis Foundation. For more information or to donate directly, visit www.fibrofoundation.org